PHARMAC documents that matched your search:
Major PHARMAC achievements in 2001-02 were: Providing new or wider access to 24 subsidised treatments, including those for raised cholesterol, multiple sclerosis, schizophrenia, epilepsy, arthritis and hay fever under cost-neutral and/or financially sustainable arrangements. Containing pharmaceutical expenditure growth by successfully negotiating savings worth approximately $36.8 million...
New Zealand will become one of the first countries in the world to fund imatinib mesylate (Glivec) as a first line treatment for chronic myeloid leukaemia, should the new therapy be approved for this use by the Ministry of Health. PHARMAC has agreed to fund Glivec for all patients for whom it is currently approved for use.